Stoke Therapeutics, Inc. (STOK): Net Income
-$6.88M
Year ended 2025-12-31
-$207.90M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$6.88M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$88.98M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$104.70M | n/m | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | -$101.07M | n/m | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | -$85.81M | n/m | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | -$52.24M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | -$32.33M | n/m | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | -$12.52M | n/a | 2020-03-23, From 2018-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | -$6.88M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$130.77M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $5.07M | -48.3% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$196.54M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $78.30M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$221.25M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$285.42M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | -$38.80M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$68.92M | n/m |
Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗